GSK chief backs affordable pricing in India

GlaxoSmithKline CEO Andrew Witty got on his soapbox in India to promote tiered drug pricing. "The setting of a price is a function of the affordability of the society in which we work," Witty said. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.